Leerink Partnrs Issues Negative Outlook for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Leerink Partnrs decreased their Q3 2025 earnings estimates for Edwards Lifesciences in a research note issued on Wednesday, December 4th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings per share of $0.60 for the quarter, down from their prior forecast of $0.62. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.55 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $2.43 EPS and FY2026 earnings at $2.84 EPS.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis.

Several other research firms have also recently weighed in on EW. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Oppenheimer reissued an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Piper Sandler lowered their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Finally, Citigroup decreased their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research report on Tuesday, October 1st. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $78.35.

Edwards Lifesciences Price Performance

Shares of EW opened at $71.53 on Monday. The company’s 50-day moving average is $68.65 and its 200-day moving average is $74.41. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $42.19 billion, a PE ratio of 10.32, a PEG ratio of 4.17 and a beta of 1.12. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Insider Activity

In related news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,000 shares of company stock worth $2,657,000. Insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in the stock. Stableford Capital II LLC lifted its holdings in Edwards Lifesciences by 2.7% in the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after buying an additional 159 shares during the period. Purus Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 5.2% in the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 160 shares during the period. Busey Bank boosted its position in shares of Edwards Lifesciences by 1.9% during the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock valued at $816,000 after purchasing an additional 165 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its stake in Edwards Lifesciences by 7.4% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 2,415 shares of the medical research company’s stock worth $224,000 after purchasing an additional 166 shares during the period. Finally, JFS Wealth Advisors LLC increased its holdings in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.